Here are the 10-Q quarterly reports from Contineum Therapeutics, Inc. (CTNM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CTNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTNM filings page.
Contineum Therapeutics, Inc. (CTNM) reported a third-quarter net loss of $18.7 million, versus $12.8 million a year earlier, with operating expenses of $21.0 million versus $14.9 million. No revenue was recognized during the three or nine months ended September 30, 2026 or 2025. Its Phase 2 PROPEL-IPF trial of PIPE-791 is underway, and management expects completion in June 2028. The FDA raised blood-pressure concerns about LPAR1 antagonists and recommended additional clinical data; the company said completed PIPE-791 trials showed no clinically relevant adverse safety signals. Janssen's Phase 2 MOONLIGHT-1 trial of PIPE-307 did not meet its primary efficacy endpoint; Janssen continues to evaluate the data.
At September 30, 2026, cash, cash equivalents and marketable securities were $244.5 million, which management expects to support operations for at least 12 months from the statements' issuance. In Q3, CTNM sold 1,409,443 shares through its at-the-market program at a weighted average price of $14.19 per share, generating $20.0 million gross and $19.4 million net proceeds. Net cash used in operations for the first nine months was $38.8 million, compared with $42.3 million in 2025.
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for inflammatory and fibrotic diseases. Lead asset PIPE-791, an LPAR1 inhibitor, is in PROPEL-IPF, a global Phase 2 trial in idiopathic pulmonary fibrosis, and has shown encouraging Phase 1b data in chronic pain. Partnered drug PIPE-307, an M1 receptor inhibitor licensed to J&J, is in a Phase 2 depression study (Moonlight-1) with 107 participants enrolled.
For the quarter ended June 30, 2026, the company reported no revenue, operating expenses of $17.4 million and a net loss of $15.2 million, or $0.40 per share$24.3 million and general and administrative expenses were $10.0 million, leading to a six‑month net loss of $29.6 million.
Liquidity remains strong, with $236.6 million in cash, cash equivalents and marketable securities as of June 30, 2026. Management states these resources are expected to fund operations for at least 12 months. An amended at‑the‑market program permits up to $100.0 million of additional Class A common stock sales, none of which were used in the first half of 2026.
Contineum Therapeutics reported Q1 2026 results showing a net loss of $14.5 million, slightly improved from $16.0 million a year earlier, as it continues investing in its neuroscience, inflammation and immunology pipeline.
Research and development expenses were $11.6 million, down from $13.7 million, mainly as trials for PIPE-307 and earlier PIPE-791 studies wound down, partly offset by spending on the new Phase 2 IPF trial for PIPE-791. General and administrative costs rose to $5.3 million, driven largely by higher stock-based compensation and headcount.
Cash, cash equivalents and marketable securities totaled $246.3 million as of March 31, 2026, and management believes this will fund operations for at least 12 months. The company amended its at-the-market program to allow up to $100.0 million of additional Class A share sales but did not use it in the quarter. Contineum highlighted positive Phase 1b chronic pain data for PIPE-791 and ongoing collaboration with J&J on PIPE-307, including J&J’s Phase 2 Moonlight-1 depression trial.
Contineum Therapeutics (CTNM) reported a Q3 2025 net loss of $12.8 million, driven by research and development of $11.0 million and general and administrative expense of $3.9 million. Interest income was $2.0 million, partially offsetting operating costs.
Liquidity remains strong with $182.4 million in cash, cash equivalents and marketable securities as of September 30, 2025. Management states these resources are sufficient for at least 12 months. During the quarter, the company activated its at-the-market program, selling 3,241,110 Class A shares at a weighted average price of $6.04 for $19.0 million in net proceeds.
Pipeline execution continued. PIPE-791 completed Phase 1 and Phase 1b PET work; a global Phase 2 in idiopathic pulmonary fibrosis is planned for Q4 2025, and an exploratory Phase 1b chronic pain trial began dosing in March 2025 with topline data expected in the first half of 2026. PIPE-307, partnered with J&J, has a fully enrolled Phase 2 RRMS trial with topline results targeted for Q4 2025, and J&J initiated a Phase 2 study in major depressive disorder in December 2024.